Hsbc Holdings PLC Acquires 48,310 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Hsbc Holdings PLC boosted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 132.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,817 shares of the biotechnology company's stock after purchasing an additional 48,310 shares during the period. Hsbc Holdings PLC owned approximately 0.17% of REGENXBIO worth $629,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Barclays PLC boosted its holdings in REGENXBIO by 141.3% in the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after purchasing an additional 67,948 shares during the period. GAMMA Investing LLC lifted its holdings in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 2,510 shares during the period. Assenagon Asset Management S.A. lifted its holdings in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after purchasing an additional 296,700 shares during the period. Hennion & Walsh Asset Management Inc. lifted its holdings in REGENXBIO by 8.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company's stock worth $1,273,000 after purchasing an additional 13,014 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in REGENXBIO in the fourth quarter worth about $1,062,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Analysts Set New Price Targets

RGNX has been the topic of several recent analyst reports. HC Wainwright cut their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, March 17th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Royal Bank of Canada reissued an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a research report on Tuesday, January 21st. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Finally, Morgan Stanley increased their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Price Performance

RGNX traded up $0.37 during trading on Friday, hitting $7.52. The stock had a trading volume of 872,904 shares, compared to its average volume of 849,180. The company has a 50 day moving average price of $7.32 and a 200-day moving average price of $8.00. The firm has a market cap of $376.88 million, a price-to-earnings ratio of -1.50 and a beta of 1.11. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $16.85.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. As a group, sell-side analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.